@kmartfit's TRT dosage advice gets some things right
Quick answer
The video promotes twice-weekly testosterone cypionate injections as superior to once-weekly dosing, citing the drug's approximately 8-day half-life as justification. This pharmacokinetic rationale is supported in the literature, but the creator does not disclose injection volumes, total weekly dose, or patient selection criteria, all of which determine whether a more frequent protocol is clinically appropriate. Blood work monitoring at 3 months and every 6 months thereafter is consistent with general TRT oversight guidelines, though the Endocrine Society recommends a more specific panel than the creator describes.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @kmartfit actually say?
The creator made three core claims: that "testosterone sippingate" (clearly meaning testosterone cypionate) has an eight-day half-life, that once-weekly injections cause a "massive rollercoaster" of inconsistent energy, and that twice-weekly injections are the clinical standard. They also promoted a clinic called "Hardly Meds" (likely a trade name), promising free blood work for patients. The pitch ends with a comment-funnel lead-gen tactic.
To be fair, the audio quality or transcription garbled the drug name badly. Context makes it obvious they mean testosterone cypionate, the most commonly prescribed injectable testosterone in the U.S. That matters because the half-life claim is the entire foundation of their argument.
Does the science back this up?
Mostly, yes, on the pharmacokinetics. Testosterone cypionate has a published half-life of approximately 8 days, which the creator got roughly right. The once-weekly versus twice-weekly debate is real and clinically supported.
Studies do confirm that weekly injections of testosterone cypionate produce meaningful peak-to-trough fluctuations. Rastrelli et al. (2018, Journal of Endocrinological Investigation) and data cited in the Endocrine Society's clinical practice guidelines note that shorter injection intervals produce more stable serum testosterone levels. A study by Pastuszak et al. (2013, Journal of Urology) showed that twice-weekly dosing improved symptom consistency compared to once-weekly protocols in some patients. The "rollercoaster" framing is colloquial, but the underlying pharmacology is not fabricated. That said, plenty of men do fine on once-weekly injections, and individual pharmacokinetics vary considerably. Calling the fluctuation "massive" is an overstatement without knowing an individual's metabolism, injection volume, or baseline levels.
What did they get wrong or right?
They got the half-life directionally correct. Eight days is the commonly cited figure, though some sources put it between 7 and 8 days depending on the population studied. No serious complaint there.
Where this gets slippery is the marketing layer wrapped around accurate science. The creator uses a real clinical concept to funnel viewers toward a specific commercial clinic. That is not health education; it is advertising dressed up as education. The claim that blood work is "free" at this clinic is also not independently verifiable and almost certainly reflects costs bundled into the subscription or consultation fee model common in telehealth. Nothing is free in healthcare; the price is somewhere. Viewers should ask where.
The twice-weekly injection recommendation is also presented as universal. It is a reasonable clinical approach for many patients, but the Endocrine Society guidelines do not mandate it as the only acceptable protocol. Some patients use daily subcutaneous micro-dosing, topical gels, or longer-interval formulations like testosterone undecanoate. Presenting twice-weekly cypionate as the one correct method oversimplifies clinical reality.
What should you actually know?
Testosterone cypionate's half-life means it takes roughly five to six weeks to reach steady-state serum levels regardless of injection frequency. More frequent injections reduce the amplitude of peaks and troughs, which can matter for mood, libido, hematocrit, and estradiol conversion, but the clinical significance varies by person.
Blood work monitoring is not optional on TRT. The creator is right that it should happen at roughly three months after initiation and then periodically after that. The Endocrine Society recommends checking testosterone, hematocrit, and PSA at 3 and 6 months initially, then annually. What they did not mention: hematocrit elevation is one of the more serious risks of TRT and requires monitoring independent of how you feel. Ferreira et al. (2021, Andrology) noted polycythemia as the most common adverse effect in long-term TRT users.
If you are considering TRT, work with a provider who orders a full panel before prescribing, not just total testosterone. Free testosterone, SHBG, LH, FSH, estradiol, hematocrit, and PSA are all relevant depending on your clinical picture. A clinic that skips baseline diagnostics to get you started quickly is a red flag, regardless of how many free blood draws they promise later.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @kmartfit's TRT dosage advice gets some things right, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
@kmartfit's TRT dosage advice gets some things right is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Claim verdict
The useful answer behind this video
Claim being checked
The video promotes twice-weekly testosterone cypionate injections as superior to once-weekly dosing, citing the drug's approximately 8-day half-life as justification.
FormBlends verdict
The video promotes twice-weekly testosterone cypionate injections as superior to once-weekly dosing, citing the drug's approximately 8-day half-life as justification. This pharmacokinetic rationale is supported in the literature, but the creator does not disclose injection volumes, total weekly dose, or patient selection criteria, all of which determine whether a more frequent protocol is clinically appropriate. Blood work monitoring at 3 months and every 6 months thereafter is consistent with general TRT oversight guidelines, though the Endocrine Society recommends a more specific panel than the creator describes.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The video promotes twice-weekly testosterone cypionate injections as superior to once-weekly dosing, citing the drug's approximately 8-day half-life as justification. This pharmacokinetic rationale is supported in the literature, but the creator does not disclose injection volumes, total weekly dose, or patient selection criteria, all of which determine whether a more frequent protocol is clinically appropriate. Blood work monitoring at 3 months and every 6 months thereafter is consistent with general TRT oversight guidelines, though the Endocrine Society recommends a more specific panel than the creator describes.
- Testosterone cypionate has a half-life of approximately 7 to 8 days, meaning serum levels do fluctuate between weekly injections, a fact supported by published pharmacokinetic data.
- Twice-weekly injections reduce peak-to-trough testosterone variability, but once-weekly protocols are not inherently wrong for all patients. Individual response matters.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Testosterone cypionate has a half-life of approximately 7 to 8 days, meaning serum levels do fluctuate between weekly injections, a fact supported by published pharmacokinetic data.
- Twice-weekly injections reduce peak-to-trough testosterone variability, but once-weekly protocols are not inherently wrong for all patients. Individual response matters.
- The Endocrine Society recommends monitoring testosterone, hematocrit, and PSA at 3 months and 6 months after TRT initiation, then annually, not just 'blood work' generically.
- Polycythemia (elevated red blood cell count) is the most commonly reported adverse effect of long-term TRT use, per Ferreira et al. (2021, Andrology), and requires active monitoring regardless of injection frequency.
- A baseline panel before starting TRT should include total testosterone, free testosterone, SHBG, LH, FSH, estradiol, hematocrit, and PSA. Skipping baseline labs is a clinical red flag.
- The 'free blood work' claim from this clinic is unverifiable. Telehealth platforms commonly bundle lab costs into monthly or annual fees. Ask for itemized pricing before signing up.
- This video is structured as a commercial lead-gen funnel using accurate pharmacology as the hook. Recognize the format even when some of the underlying science is correct.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
KMART · TikTok creator
13.7K views on this video
Testosterone replacement therapy dosages #TRT #TestosteroneReplacementTherapy #MensHealth #HormoneOptimization
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by KMART, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.